# Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])

> **NCT02741544** · — · COMPLETED · sponsor: **Celgene** · enrollment: 578 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02741544
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-03
- **Primary completion:** 2020-08-20
- **Final completion:** 2020-08-20
- **Target enrollment:** 578 (ACTUAL)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02741544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02741544, "Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02741544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*